ANNUAL MEETING
8-10/6/2017
DAN EILAT HOTEL

Hot Topics in Hepatology

Scientific Program
THURSDAY JUNE 8TH, 2017

11:00-13:00  Liver Forum  
"Blue" Hall | Moderator: Dr. Yoav Lurie  
Sponsored by abbvie | GILEAD

11:00-11:24  In the Footsteps of the Liver  
Dr. Tamar Berger, Beilinson Hospital

11:24-11:48  DECOPPERING - מחלת וילסון: נחושים לא  
Dr. Ella Wiezmann, Rambam Medical Center

11:48-12:12  Tacrolimus Vs Cyclosporine after liver transplantation  
Dr. Oranit Cohen-Ezra, Tel Hashomer

12:12-12:36  Treating Hepatitis C beyond AASLD/EASL recommendations  
Dr. Yaakov Maor, Kaplan Medical Center

12:36-13:00  "אני רק שאלה"  
Dr. Yoav Lurie, Shaare Zedek

13:00-13:30  Light Lunch

13:30-13:45  Opening  
"Blue" Hall

13:30-13:35  Greetings  
Prof. Eli Zuckerman, IsASL Chairman

13:35-13:45  Hepatology 2017 - לאן?  
Prof. Ran Tur-Kaspa, Director, Liver Institute, Beilinson Hospital
13:45-15:55  SESSION 1: Toxic Liver Disease, fibrosis & Cholestasis
“Blue” Hall
Chairs: Prof. Rafi Bruck, Dr. Rawi Hazan

13:45-10:53  Novel anti-LOXL2 inhibitor paves the way for macrophage-mediated collagen degradation in experimental liver fibrosis
Mordehay Kelpfish 2, Milena Vugman 1, Eli Brazowski 1, Chen Varol 1, Irit Sagi 2
1 The Research Center for Digestive Tract and Liver Diseases and Department of Clinical Microbiology and Immunology, Tel-Aviv Sourasky Medical Center and Tel-Aviv University, Israel
2 Department of Biological Regulation, Weizmann Institute of Science, Israel

13:53-14:01  The PARP-1 inhibitor 3-aminobenzamide prevents Concanavalin A-induced acute hepatitis in mice by a joint anti-inflammatory and anti-oxidative mechanism
Joram Wardi 1, Orna Ernst 4, Anna Lilja 4, Hussein Aeed 1, Sebastian Katz 4, Dolev Katz 4, Olga Bernadsky 2, Rajendar Kandhikonda 5, Yona Avni 1, Roy Weinstein 3, Alexander Biro 3, Tsaffrir Zor 4
1 Gastroenterology, Wolfson Medical Center, Israel, 2 Pathology, Wolfson Medical Center, Israel, 3 Nephrology, Wolfson Medical Center, Israel, 4 Biochemistry and Life Sciences, Life Sciences, Tel-Aviv University, Israel, 5 Molecular biology & ecology of plants, Tel-Aviv University, Life Sciences, Israel

14:01-14:09  Thiopurine metabolites measurement in adult patients with autoimmune hepatitis
Hisham Sholy, Ella Veitsman, Tarek Saadi
Liver unit, Rambam Health Care Campus, Israel
Namodenoson (CF102) Prevents Progression of Liver Fibrosis
Johnny Amer¹, Rifaat Safadi¹, Ahmad Salhab¹, Shira Cohen², Pnina Fishman²
¹ Liver & Gastroenterology Units, Hadassah-Hebrew University Hospital, Israel, ² Can-Fite BioPharma Ltd., Can-Fite BioPharma Ltd., Israel

Metabolic and cardiovascular co-morbidities are associated with severe complications following Transjugular Intrahepatic Portosystemic Shunt: a 10 year single center experience
Neta Gotlieb¹, Jonathan Brill², Shiri Sherf Dagan¹, Isaac Kori³, Oren Shibolet¹
¹ Department of gastroenterology and liver diseases, Tel-Aviv medical center and the Sackler faculty of medicine, Tel-Aviv, Israel, ² Sackler faculty of medicine, Tel-Aviv university, Tel-Aviv, Israel, ³ Interventional radiology, Tel-Aviv medical center and the Sackler faculty of medicine, Tel-Aviv, Israel

Effect of the autonomic nervous system on splanchnic circulation before and after meals
Farid Zreik, Reshef Meshulam, Oren Shibolet, Jacob Giris
Medicine F, J. Recanati Autonomic Dysfunction Center, Tel Aviv Sourasky Medical Center & Faculty of Medicine, Israel

Amiodarone induced adipose tissue endoplasmic reticulum stress and lipolysis may contribute to hepatic lipid accumulation
Einav Hubel-Manor, Inbal Houri, Roy Avraham, Isabel Zvibel, Oren Shibolet
Gastroenterology Institute, Sackler Faculty of Medicine, Tel-Aviv University, Israel
14:45-15:25  **PBC-Panoramic View of New and emerging treatments**  
*Prof. Gideon Hirschfield*  
Professor of Autoimmune Liver Disease at the University of Birmingham, and Honorary Consultant Transplant Hepatologist at Queen Elizabeth Hospital, University Hospitals Birmingham, UK  
Sponsored by  

15:25-15:50  **Coffee Break, Visit to the Poster Exhibit & Exhibit Hall**  

15:50-18:00  **SESSION 2: Fibrosis, Cholestasis & Viral Hepatitis**  
*“Blue” Hall*  
*Chairs: Dr. Amir Shlomai, Dr. Tarek Saadi*  

15:50-16:00  **The Dual CCR2/CCR5 Inhibitor Cenicriviroc Ameliorates Murine Primary Biliary Cholangitis**  
*Debby Reuveni¹, Debby Reuveni¹, Ayelet Kaminitz¹, Siwar Assi¹, Patrick Leung³, Pamela Vig⁴, Eli Brazowski², Oren Shibolet¹, Eric Gershwin³, Ehud Zigmond¹*  
¹The Research Center for Digestive Diseases, Gastroenterology and Liver disease institute, Tel Aviv-Sourasky Medical Center, Israel, ²Department of Pathology, Sourasky Medical Center, Israel, ³Division of Rheumatology, Allergy and Clinical Immunology, University of California at Davis, USA  
⁴Allergen, Allergen plc, USA  

16:00-16:20  **Hot Topic 1-PSC -Clinical challenges in practice**  
*Prof. Gideon Hirschfield*  
Professor of Autoimmune Liver Disease at the University of Birmingham, and Honorary Consultant Transplant Hepatologist at Queen Elizabeth Hospital, University Hospitals Birmingham, UK
16:20-16:28  **Point Shear Wave Elastography Method for Assessing Liver Stiffness in Different Etiologies of Liver Diseases – A Prospective study**

Tarek Saadi¹, Johad Khoury¹, Widad Toukan¹, Hisham Sholy¹, Rimma Krimsky¹, Vered Ben Hakoon¹, Ella Veitzman¹, Yaakov Baruch¹, Diana Gaitini²

¹Liver Unit, Rambam: Human Health Care Campus, Haifa, Israel
²Radiology department, Rambam: Human Health Care Campus, Haifa, Israel

16:30 -17:15  **HCV: lesson learned from clinical studies to real world data**

Prof. Steven Flamm
Division of Hepatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
Sponsored by MSD

17:15-17:23  **Vitamin D antagonizes the expression of genes that are epigenetically regulated by Hepatitis C virus**

Romy Zemel¹, Noa Rapaport¹, Shira Perez²³, Efeedal Morad³, Marcela Karpuj⁴, Amiram Ravid⁵, Meital Gal-Tanamy², Izhak Haviv³, **Ran Tur-Kaspa**⁶⁷

¹Molecular Hepatology Lab., Tel-Aviv University, FMRC, Israel
²Molecular Virology Lab., Bar-Ilan University, Faculty of Medicine in the Galilee, Israel
³Cancer Personalized Medicine and Diagnostic Genomics Lab, Bar-Ilan University, Faculty of Medicine in the Galilee, Israel
⁴Genomic Center, Bar-Ilan University, Faculty of Medicine in the Galilee, Israel
⁵Molecular Endocrinology, Tel-Aviv University, FMRC, Israel
⁶Liver Institute, Rabin Medical Center, Beilinson Hospital, Israel
⁷Faculty of Medicine in the Galilee, Bar-Ilan University, Israel
17:25-17:55  **Novel treatment options for Hepatitis B and D Virus infection: Entry Inhibition as a potent concept to prevent intrahepatic spread of HBV cccDNA and HDV RNA**  
*Prof. Stephan Urban*  
Head, Translational Virology unit, Department of Infectious Diseases, Molecular Virology Heidelberg University Hospital, Germany

17:55-18:10  **Coffee Break, Visit at the Poster Exhibit & Exhibit Hall**

18:10-19:30  **SESSION 3: Viral Hepatitis**  
“Blue” Hall  
*Chairs: Dr. Tania Berdichevski, Dr. Marius Braun*

18:10-18:18  **Increased killer B cells: Are they associated with increased viral load and autoimmunity in patients with chronic HCV infection?**  
*Eli Zuckerman*¹, Nasren Eiza², Mattias Karlebach³, Tova Rainess³, Yair Goldberg², Elias Toubi², Zahava Vadasz²  
¹ Liver Unit, Carmel Medical Center, Technion Faculty of Medicine, Israel  
² Division of Allergy & Clinical Immunology, Bnai Zion Medical Center, Israel  
³ Institute of Gastroenterology, Bnai Zion Medical Center, Israel

18:20-19:05  **It’s all about the Pan- moving forward with HCV treatment**  
*Dr. Ashley Brown*  
Consultant Hepatologist, Imperial College Healthcare NHS Trust St. Mary’s Hospital, UK  
Sponsored by *abbvie*
Prospective assessment of the impact of successful DAAs treatment on liver fibrosis stage and predictors of fibrosis regression in patients with chronic hepatitis C

Yana Davidov-Derevyanko 1, Yeruham Kleinbaum 1,3, Yael Inbar 1,3, Oranit Cohen-Ezra 1,4, Ella Veitsman 2, Tanya Berdichevsky 1, Perez Weiss 1, Maria Lihter 1, Sima Katerginsky 1,3, Avishag Hassid 1, Keren Tzaraf 1, Ziv Ben-Ari 1,4

1 Liver Disease Center, Sheba Medical Center, Israel
2 Liver Disease Center, Rambam Medical Center, Israel
3 Department of Radiology, Sheba Medical Center, Israel
4 Sackler School of Medicine, Tel Aviv University, Israel
## PARALLEL SESSION - NURSES

07:30-09:30

### Extrahepatic HCV manifestations

07:30-08:30

**פרופ’ אליעזר צוקרמן**

לייווי וניטחון ושיתוף הפעולה עם יהודי ה-

08:30-08:45

**רימה קרמסקי, א. אחראית יחידת כבד مركز רפואית רמב”ם**

 места האחיות והמתאמות מחקר

08:45-09:00

**יעל חריף, א. אחראית יחידת כבד מרכז רפואי בלינסון**

**ביופסיית כבד - איסוף והמשולך של שלטי דם**

09:00-09:15

**קרן צארף, א. אחראית יחידת כבד מרכז רפואי שיבא**

**אנטרו פפטיטיס C**

09:15-09:30

**אורלי אזולאי, א. אחראית יחידת כבד מרכז רפואית כרמל**

### SESSION 4: Non Alcoholic Fatty Liver disease, Viral Hepatitis

08:00-09:30

**“Blue” Hall**

**Chairs: Prof. Rifaat Safadi, Dr. Michal Carmiel-Hagai**

**NK cell apoptosis correlates with fibrosis progression in Nonalcoholic-Fatty Liver-Disease via insulin receptor and mTOR pathway**

**Johnny Amer, Ahmad Salhab, Sarit Doron, Rifaat Safadi**

Liver & Gastroenterology Units, Hadassah-Hebrew University Hospital, Israel
Circulating Levels of the Chemokine CCL24 and its Receptor in Patients with Non-alcoholic Fatty Liver Disease
Yaakov Maor¹, Dan Haberman², Michal Segal-Salto³, Avi Katav³, Sharon Hashmueli³, Jacob George², Adi Mor³
¹Institute of Gastroenterology and Hepatology, Kaplan Medical Center, Israel, ²Heart Center, Kaplan Medical Center, Rehovot, Affiliated to the Hebrew university, Jerusalem, Israel
³NA, ChemomAb ltd, Israel

CM-101, a novel CCL24 blocking monoclonal antibody ameliorates hepatic injury in NASH induced mouse model
Ziv Ben-Ari¹, Michal Segal-Salto², Avi Katav², Sharon Hashmueli², Jacob George³, Dan Haberman³, Yaacov Maor⁴, Adi Mor²
¹Liver Diseases Center, Sheba Medical Center, Israel,
²Chemomab, ChemomAb Ltd, Israel, ³Heart Institute, Kaplan Medical Center, Israel, ⁴Liver Diseases service, Kaplan Medical Center, Israel

Non-alcoholic Fatty Liver Disease in Non-obese Young Adults
Yaakov Maor¹, Salah Daher²,³, Eran Israeli³, Stephen DH Malnick⁴, Ehud Melzer¹, Lior Katz⁵
¹Institute of Gastroenterology and Hepatology, Kaplan Medical Center, Israel, ²NA, the Israeli Defense Force, Israel
³Department of Gastroenterology and Hepatology, Hadassah Medical Center, Israel, ⁴Department of Internal Medicine C, Kaplan Medical Center, Israel, ⁵Department of Gastroenterology, Sheba Medical Center, Tel-Hashomer, Israel

The association of dietary meat type and its cooking method with non-alcoholic fatty liver disease and insulin resistance
Dana Ivancovsky¹, Revital Kariv²,³, Naomi Fliss-Isakov²,³, Muriel Webb²,³, Oren Shibolet²,³, Shira Zelber-Sagi¹,²
¹University of Haifa, School of Public Health, Israel
²Tel Aviv Medical Center, Department of Gastroenterology, Israel, ³Tel Aviv University, Faculty of Medicine, Israel
08:40-08:48  The impact of bariatric surgery on nonalcoholic fatty liver disease and cardiovascular risk utilizing non-invasive measures
Carmit Netanel\textsuperscript{1}, David Goitein\textsuperscript{2}, Moshe Rubin\textsuperscript{2,3}, Michael Shechter\textsuperscript{3,4}, Yeruham Kleinbaum\textsuperscript{5}, Sima Katsherginsky\textsuperscript{5}, Hila Hermon\textsuperscript{2}, Rina Hemi\textsuperscript{6}, Keren Tsaraf\textsuperscript{1}, Ardita Donuzi\textsuperscript{1}, Michal Safran\textsuperscript{1}, Irina Tachlytski\textsuperscript{1}, Amir Herman\textsuperscript{3,7}, Pablo Ortiz\textsuperscript{8}, Ziv Ben-Ari\textsuperscript{1,3}
\textsuperscript{1} Liver Disease Center, Sheba Medical Center, Tel Hashomer, Israel, \textsuperscript{2} Bariatric and Metabolic Surgery, Sheba Medical Center, Tel Hashomer, Israel, \textsuperscript{3} Sackler School of Medicine, Tel Aviv University, Israel, \textsuperscript{4} Leviev Heart center, Sheba Medical Center, Tel Hashomer, Israel, \textsuperscript{5} Deparment of Radiology, Sheba Medical Center, Tel Hashomer, Israel, \textsuperscript{6} Institute of Endocrinology, Sheba Medical Center, Tel Hashomer, Israel, \textsuperscript{7} Department of Orthopedics, Sheba Medical Center, Tel Hashomer, Israel, \textsuperscript{8} OWL, Parque Tecnológico de Bizkaia, Spain

08:48-08:56  Predictors of minimal hepatic encephalopathy in asymptomatic HCV patients before and after antiviral treatment. Preliminary results from the EMERALD study
Sharon Levy, Nir Bar, Oren Shibolet, Helena Katchman
Liver unit, Department of Gastroenterology and Liver Diseases, Tel-Aviv Sourasky medical center and the Sackler faculty of medicine, Israel

09:00-09:20  Hot topic 2: Withdrawal NUCs in HBeAg-negative patients
Dr. Ashley Brown
Consultant Hepatologist, Imperial College Healthcare NHS Trust St. Mary’s Hospital, UK
09:20-09:28  **Hepatitis delta seroprevalence and molecular characterization of hepatitis B and delta confection in Israel**
Rachel Shirazi¹, Daniela Ram¹, Aviya Rakovsky¹, Efrat Bucris¹, Yael Gozlab¹, Pninit Shaked-Mishan², Orit Picard³, Yonat Shemer-Avni⁵, Haim Ben-Zvi⁶, Ora Halutz⁸, Ella Mendelson¹, Rifaat Safadi⁹, Yoav Lurie⁷, Ziv Ben-Ari⁴, **Orna Mor¹**  
¹ Central Virology Laboratory, Ministry of Health, Israel  
² Microbiology Laboratory, Carmel Medical Center, Israel  
³ Gastroenterology Laboratory, Sheba Medical Center, Israel  
⁴ Liver Disease Center, Sheba Medical Center, Israel  
⁵ Microbiology Laboratory, Soroka Medical Center, Israel  
⁶ Microbiology Laboratory, Rabin Medical Center, Israel  
⁷ Liver Unit, Shaare Zedek Medical Center, Israel  
⁸ Microbiology Laboratory, Sourasky Medical Center, Israel  
⁹ Liver Unit, Hadassah Medical Center, Israel

09:30-09:55  **Coffee Break, Visit to the poster exhibit & Exhibit Hall**

10:05-11:31  **SESSION 5: Hepatocellular carcinoma**

**Blue** Hall  
Chairs: Dr. Yaakov Maor, Dr. Yoram Menachem  
Sponsored by [Gilead](https://gilead.com)

10:05-10:13  **Occurrence and Recurrence of Malignancies Post DAA Treatment in 5.1% of Patients - Single Center Experience**
Assaf Issachar, Orly Sneh-Arbib, Marius Braun, Amir Shlomai, Evelin Oxtrud, Chen Karuani, Hagar Banai, Yael Harif, Ran Tur-Kaspa, Michal Cohen-Naftali  
Liver Institute, Rabin Medical Center-Beilinson Hospital, Israel

10:15-10:35  **Hot topic 3 - Occurrence and recurrence of HCC with DAAs treatment for HCV**
Prof. Steven Flamm  
Division of Hepatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
10:35-10:43 Cutting the Israeli Hepatitis C related “Hepatocellular Carcinoma” in 2016
Izhar Levy 1, Vered ben-Hakoon 2, Rawi Hazzan 3, Tova Nesher 1, Igbaria Saleh 3, Alexander Shtarkman 3, Ravit Geva 5, Tarek Saadi 2, Ella Veitsman 2, Oren Shibolet 4, Rifaat Safadi 1, Yoram Menachem 4
1 Liver unit, Hadassah Hospital, Israel, 2 Liver unit, Rambam Hospital, Israel, 3 Liver unit, HaEmek Hospital, Israel, 4 Liver unit, Ichilov Hospital, Israel, 5 Oncology, Ichilov Hospital, Israel

10:43-10:51 Hepatitis C virus infection is associated with increased rate of malignancy other than B-cell lymphoma and HCC
Eli Zuckerman 1, Hedy S. Rennert 2, Gad Rennert 2
1 Liver Unit, Carmel Medical Center, Israel, 2 Department of Community Medicine and Epidemiology, Carmel Medical Center, Technion Faculty of Medicine, Israel

10:51-10:59 High-resolution liver cancer genomic profiling links etiology, epigenetic and mutation signatures
Meital Gal-Tanamy 1, Shira Perez 1,2, Anat Lavi-Itzkovitz 1,3, Antony Kaspi 4, Ateret Davidovich 1, Ana Tobar 5, Alejandro Livoff 6, Assy Nimer 7, Evgeny Solomonov 8, Assam El-Osta 4, Gur Yaari 3, Salomon M Stemmer 9, Izhak Haviv 2
1 Molecular Virology Lab, Faculty of Medicine in the Galilee, Bar-Ilan University, Israel 2 Cancer Personalized Medicine and Diagnostic Genomics Lab, Faculty of Medicine in the Galilee, Bar-Ilan University, Israel 3 Bioengineering, Faculty of Engineering, Bar-Ilan University, Israel 4 Epigenetics in Human Health and Disease Laboratory, Department of Diabetes, Central Clinical School, Monash University, Australia 5 Institute of Pathology, Rabin Medical Center, Beilinson Campus, Israel 6 Department of Pathology, Barzilay Medical Center, Israel 7 Internal Medicine Department A, Western Galilee Medical Center, Israel 8 Department of Surgery, Ziv Medical Center, Israel 9 Davidoff Center, Rabin Medical Center, Beilinson Campus, Israel
Fecal microbiota profiles as diagnostic biomarkers in cirrhosis and hepatocellular carcinoma and the impact of life style and nutrition

Lena Lapido†1,2,3, Rita Nosenko4, Bella Gayshis2, Maria Likhter2, Wadia Hazou2, Dana Ben-Ami2, Tatiana Bradichevsky2, Ofir Harnoy2, Tal Engel2, Itai Kalisky2, Peretz Weiss2, Ella Veitsman2, Oranit Cohen-Ezra2, Yana Davidov2, Omry Koren6, Michal Safran1,2, Ziv Ben-Ari2,3

1 Liver research laboratory, Chaim Sheba Medical Center, Tel-Hashomer, Israel 2 Liver Diseases Center, Chaim Sheba Medical Center, Tel-Hashomer, Israel 3 The Sackler School of Medicine, Tel-Aviv University, Israel 4 Faculty of Medicine, Bar-Ilan University, Israel

The potential of curcumin in combination with direct acting antivirals to treat Hepatitis C virus infection and prevent viral induced oncogenesis

Oshri Yosefov Levi1, Ateret Davidovich1, Shimon Steingart2, Yoav Lurie2, Meital Gal Tanamy1

1 Molecular Virology, Bar Ilan University faculty of medicine in the galilee, Israel 2 Digestive Disease Institute, Shaare Zedek Medical Center, Israel

Role of Lens culinaris Agglutinin-Reactive Fraction of α-Fetoprotein (AFP-L3) and Des-Gamma-Carboxy Prothrombin (DCP), Alone or in Combination, as Biomarkers for Hepatocellular Carcinoma surveillance

Ziv Ben-Ari1,3, Gal Ben-Haim1, Ella Weitzman1, Oranit Cohen-Ezra1,3, Peretz Wiess1, Tania Berdichevsky1, Itai Kalisky1, Dana Silverberg1, Shani Dor-Hai1, Avishag Hassid1, Keren Tzaref1, Orly Azoulay2, Eyal Ashkenazi2, Yulia Kovalev2, Eli Zuckerman2,4

1 Liver Diseases Center, Sheba medical Center, Israel 2 Liver Unit, Carmel Medical Center, Israel 3 Sackler School of Medicine, Tel Aviv University, Israel 4 Rappaport Faculty of Medicine, Technion, Israel
Distinct antibody-mediated immune response against HCV correlates with spontaneous viral clearance

Anastasia Brodov1, Yoav Bahat1, Ateret Davidovich1, Sivan Elyahu1, Shiri Elmedvi1, Yael Weiss2, Jonathan Gershoni2, Marius Braun3, Assy Nimer4, Meital Gal-Tanamy1

1Molecular Virology Lab, Faculty of Medicine in the Galilee, Bar-Ilan University, Israel 2Virology and Immunology Lab, Faculty of Biology, Tel Aviv University, Israel 3Liver Institute, Rabin Medical Center, Sackler School of Medicine, Tel-Aviv University, Israel 4Liver Institute, Western Galilee Hospital, Nahariya, Israel

Coffee Break, Visit to the poster Exhibit & Exhibit Hall

SESSION 6: Viral Hepatitis

“Blue” Hall
Chairs: Dr. Ohad Ezion, Dr. Matthias Carlebach
Sponsored by Gilead

Hot Topic 4 - Reactivation of HBV during treatment for HCV with DAAs
Prof. Daniel Shouval
Liver Unit, Hadassah- Hebrew University Hospital, Ein- Kerem

The Real-World Israeli experience of treating chronic hepatitis C, genotype 1 and 4 patients with advanced fibrosis with grazoprevir plus elbasvir: a large multi-center cohort
Eli Zuckerman1, Eyal Ashkenazi1, Yulia Kovalev1, Oranit Cohen Ezra1, Ella Weitzman3, Tarek Saadi3, Matthias Carlebach4, Rawi Hazzan5, Rifaat Safadi6, Tova Goldberg6, Ran Oren6, Yafa Ashur7, Michal Carmiel8, Yona Kitayi9, Ruth Hadari9, Seif Abu-Mouch10, Rafael Bruk Bruk11, Yoram Menachem11, Helena Kathcman11, Oren Shibolet11, Orly Sneh12, Haim Shirin13, Ran Tur-Kaspa14, Marius Broun14, Michal Cohen Naftaly14, Amir Shlomai14

1Liver Unit, Carmel Medical Center, Technion Faculty of Medicine, Israel 2Center of Liver Diseases, Sheba Medical Center, Israel 3Liver Unit, Rambam Medical Center, Israel 4Liver Unit, Bnai Zion Medical Center, Israel 5Liver Clinic, Ha’emek
Medical Center, Israel 6 Liver Unit, Hadassah Medical Center, Israel 7 Liver Clinic, Southern District, CHS, Israel 8 Liver Clinic, Western Galilee Medical Center, Israel 9 Liver Clinic, Meir Medical Center, Israel 10 Liver Unit, Hillel Yaffe Medical Center, Israel 11 Liver Unit, Tel Aviv Medical Center, Israel 12 Liver Clinic, Talpiot Clinic, CHS, Israel 13 Department of Gastroenterology, Assaf Harofeh Medical Center, Israel 14 Liver Institute, Rabin Medical Center, Israel

12:18-12:26  **Vertical HBV transmission in North West Galilee**
Jamalat Jaas 1, Rifaat Safadi 2, Shihab Shihab 1
1 Acre Health Bureau, Israeli Ministry of Health, Akco District, Israel 2 Liver and Gastroenterology Units, Hadassah-Hebrew University Hospital, Israel

12:26-12:34  **Hepatitis B virus infection after the implementation of the vaccine program in Israel**
Eli Zuckerman 1, Hedy S. Rennert 2, Gad Rennert 2
1 Liver Unit, Carmel Medical Center, Technion Faculty of Medicine, Israel 2 Community Medicine and department of Epidemiology, Carmel Medical Center, Israel

12:34-12:42  **Hepatitis E Virus in Israeli HIV Infected Patients**
Rasha Daniel 1,2,4, Shira Zelber-Sagi 2, Margalit Lorber 3, Mira Barak 4, Orly Azulay 1, Eli Zuckerman 1
1 Liver Unit, Carmel Medical Center, Israel 2 Faculty of Public Health, Haifa University, Israel 3 Autoimmune, HIV/AIDS Disease Unit, RAMBAM Medical Center, Israel 4 Nesher Central Laboratories, Haifa and Western Galilee District, CHS, Israel
12:42-12:50  Automated Low Flow Pump System (AlFAPUMPÓ) For the Treatment of Refractory Ascites- Initial Israeli Experience
Michal Cohen1,3, Asaf Issachar1,3,4, David Arnovitz2,3, Orly Sneh-Arviv1,3, Amir Shlomai1,3,4, Ran Tur Kaspa1,5, Marius Braun1,3
1 Liver Unit, Beilinson Hospital, Israel 2 General Surgery Department, Beilinson Hospital, Israel 3 Sackler Faculty of Medicine, Tel Aviv University, Israel 4 Internal Medicine Department D, Beilinson Hospital, Israel 5 Faculty of Medicine, Bar Ilan University, Israel

12:50-13:00  Mr. Hulio Burman - Hetz

13:00-13:30  Business Meeting

13:30-14:30  Lunch - Hotel’s Restaurant
Dr. Ashley Brown is a Consultant Hepatologist at St Mary’s Hospital, Paddington and Adjunct Reader in Medicine at Imperial College London. He has a major clinical and research interest in viral hepatitis, has been investigator on more than 40 clinical trials of novel hepatitis therapies and has published nearly 50 papers in peer-reviewed journals. He is currently heavily engaged in developing policy for ensuring access and pathways into care for difficult-to-reach populations, including prisoners and PWID, and looking at the health economics of screening for and treating HCV. He is former Chair of the London Joint Working Group on HCV in PWID and of the British Viral Hepatitis Group; he sits on the HepC Coalition; and has recently been co-opted onto the European Liver Patients’ Association Task Force.

Professor Stephan Urban is head of the Translational Virology unit at the Department of Infectious Diseases, Molecular Virology at Heidelberg University Hospital. He is also Professor at the Faculty for Biosciences at the University of Heidelberg and Project Coordinator in the DZIF TTU Hepatitis. He completed a Diploma in Biochemistry at the University of Tübingen in 1991 and was awarded a Ph.D. in 1995 under Prof. Dr. P.H. Max-Planck-Institut für Biochemie, Martinsried and undertook Postdoctoral research at the Centre for Molecular Biology (ZMBH), Heidelberg University with Prof. Dr. H. Schaller.

Between 2008 and 2012 he was Project coordinator of the BMBF-network «Innovative Therapies” and from 2011 Project coordinator in the DZIF TTU hepatitis. In 2014 he was awarded with the 1. DZIF Research Award.

Professor Urban’s research interests include Molecular mechanisms of Hepatitis B- and Hepatitis D Virus/host interactions with a focus on the early and late events of viral infection; Identification of hepadnaviral receptors and structural analyses of virus receptor interactions; Development of novel cell culture systems and animal models for HBV and HDV; Clinical development of entry inhibitors for HBV and HDV infection; Development of hepatotropic drugs for the therapy of liver diseases.

Between 2008 and 2014 Professor Urban has published in numerous peer reviewed journals on Hepatitis B, C and D. He is the recipient of the Pettenkofer Price of the Pettenkofer Foundation, Fellowship of the Heinz Schaller and Chica Foundations and Study Foundation of the German People Awards.

Steven L. Flamm, MD is a Professor of Medicine and Surgery with the Division of Hepatology at Northwestern University Feinberg School of Medicine in Chicago, Illinois. He serves as the Chief of Transplantation Hepatology and Medical Director of Liver Transplantation.

Dr. Flamm received his MD degree from the University of Pennsylvania School of Medicine. He completed both a clinical fellowship in gastroenterology and a
research fellowship in gastroenterology and hepatology at Beth Israel Hospital, Harvard Medical School. He then received further specialized training, completing a clinical fellowship in hepatology and liver transplantation at The Deaconess Hospital, Harvard Medical School. Dr. Flamm is a member of the American Gastroenterological Association (AGA), American Association for the Study of Liver Diseases (AASLD), and is a fellow in the American College of Gastroenterology (ACG). He has served as the Region 7 Representative to the UNOS Liver and Intestine Committee and on the Publication and Practice Guidelines Committees of the AASLD. Currently, he is a trustee of the AASLD Foundation and chairs the AASLD Development Committee. Dr. Flamm is also a member of the Clinical Practice Guidelines Committee of the AGA and the Illinois Hepatitis C State Task Force. Dr. Flamm was also the 2015 American Liver Foundation Illinois Chapter Honoree.

Dr. Flamm has published widely in the field of hepatic diseases and has spoken both nationally and internationally on many other liver-related topics including viral hepatitis, autoimmune hepatitis, hepatic encephalopathy, and liver transplantation. He has an active clinical research program for patients with many different chronic liver diseases including chronic viral hepatitis (HBV and HCV), hepatic encephalopathy, acute liver failure and non-alcoholic fatty liver disease (NAFLD).

Gideon Hirschfield graduated from Trinity College Oxford in 1994 (having been awarded the University of Oxford Wronker Prize for most outstanding performance in the Final Honour School), and subsequently from Cambridge where he completed his clinical studies with distinction. He undertook junior medical posts at the Hammersmith and Royal Brompton hospitals before moving to a MRC Clinical Research Fellowship at UCL. There he worked within the uniquely translational National Amyloidosis Centre/Centre for Acute Phase Proteins, with Sir Mark Pepys FRS as his supervisor. His PhD was focussed on the development of inhibitors of C-reactive protein. He completed his advanced Gastroenterology and Hepatology training in Cambridge, and was awarded Specialist status in 2007. Until January 2012 he worked in Toronto, Canada, where he was a Staff Physician and Assistant Professor of Medicine at the University Health Network and University of Toronto. During this time he managed one of the largest autoimmune liver disease cohorts in North America, and with his colleague Prof Kathy Siminovitch published the seminal genetic observations underpinning the IL-12 signalling axis as critical to the pathophysiology of PBC. He now divides his time between translational research in autoimmune liver disease, and his clinical, Transplant/Hepatology, practice at the QE hospital. In particular the cohorts of patients with PBC, PSC and AIH he manages are some of the largest internationally, providing Gideon unique clinical skills in their management and recruitment to clinical trials of novel therapies.
Sponsors

Platinum

Gilead
Advancing Therapeutics. Improving Lives.

MSD
INVENTING FOR LIFE

Gold

Abbvie

Silver

Bristol-Myers Squibb

Neopharm Israel

Bronze

MegaPharm
We Know The Way

Tzamal

Kamada
High Quality Pharmaceuticals

Abbott
A Promise for Life

Medison
Delivering innovative healthcare

ORTRA
Meeting Point